Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription initiation factor IA (TIF‐IA) is an essential transcription factor that regulates the synthesis of ribosomal RNA (rRNA) by facilitating the recruitment of RNA polymerase I to ribosomal DNA promoters. It acts as a key mediator between cellular growth signals—particularly those from the PI3K/Akt/mTOR pathway—and rRNA production. Phosphorylation events modulate its activity; for example, Akt activation enhances TIF‐IA stability and nucleolar localization via casein kinase 2–mediated phosphorylation, thereby promoting rRNA transcription and supporting cell proliferation. Conversely, downregulation or inhibition of TIF‐IA leads to reduced rRNA synthesis, impaired ribosome biogenesis, developmental arrest in model organisms like Drosophila, and decreased cell viability. Due to its central role in controlling protein biosynthesis capacity through ribosome production—and thus influencing cancer cell growth—TIF‐IA is considered a potential therapeutic target in oncology research.
Inhibition of upstream signaling pathways (PI3K/Akt/mTOR) reduces TIF‐IA activity and rRNA synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription initiation factor IA (TIF-IA).